The Role of DOT1L in Normal and Malignant Hematopoiesis

被引:9
作者
Arnold, Olivia [1 ]
Barbosa, Karina [2 ]
Deshpande, Aniruddha J. [2 ]
Zhu, Nan [1 ]
机构
[1] Blood Res Inst, Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Versiti, Milwaukee, WI 53226 USA
[2] Sanford Burnham Prebys Med Discovery Inst, Tumor Initiat & Maintenance Program, La Jolla, CA USA
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 10卷
关键词
DOT1l; hematopoiesis; leukemia; transcription; HOX GENE-EXPRESSION; H3K79; METHYLATION; METHYLTRANSFERASE; LEUKEMIA; TRANSFORMATION; RECRUITMENT; NUCLEOSOME; REQUIRES;
D O I
10.3389/fcell.2022.917125
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Disruptor of telomeric silencing 1 (DOT1) was first identified in yeast (DOT1p) and is the sole methyltransferase responsible for histone three lysine 79 (H3K79) mono-, di-, and tri-methylation. Mammalian DOT1 (DOT1-like protein or DOT1L) has been implicated in many cellular processes, such as cell cycle progression, DNA damage response, and development. A notable developmental process reliant on DOT1L function is normal hematopoiesis, as DOT1L knockout leads to impairment in blood lineage formation. Aberrant activity of DOT1L has been implicated in hematopoietic malignancies as well, especially those with high expression of the homeobox (HOX) genes, as genetic or pharmacological DOT1L inhibition causes defects in leukemic transformation and maintenance. Recent studies have uncovered methyltransferase-independent functions and a novel mechanism of DOT1L function. Here, we summarize the roles of DOT1L in normal and malignant hematopoiesis and the potential mechanism behind DOT1L function in hematopoiesis, in light of recent discoveries.
引用
收藏
页数:7
相关论文
共 56 条
  • [11] Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l
    Chen, L.
    Deshpande, A. J.
    Banka, D.
    Bernt, K. M.
    Dias, S.
    Buske, C.
    Olhava, E. J.
    Daigle, S. R.
    Richon, V. M.
    Pollock, R. M.
    Armstrong, S. A.
    [J]. LEUKEMIA, 2013, 27 (04) : 813 - 822
  • [12] Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
    Dafflon, C.
    Craig, V. J.
    Mereau, H.
    Graesel, J.
    Engstler, B. Schacher
    Hoffman, G.
    Nigsch, F.
    Gaulis, S.
    Barys, L.
    Ito, M.
    Aguade-Gorgorio, J.
    Bornhauser, B.
    Bourquin, J-P
    Proske, A.
    Stork-Fux, C.
    Murakami, M.
    Sellers, W. R.
    Hofmann, F.
    Schwaller, J.
    Tiedt, R.
    [J]. LEUKEMIA, 2017, 31 (06) : 1269 - 1277
  • [13] Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
    Daigle, Scott R.
    Olhava, Edward J.
    Therkelsen, Carly A.
    Majer, Christina R.
    Sneeringer, Christopher J.
    Song, Jeffrey
    Johnston, L. Danielle
    Scott, Margaret Porter
    Smith, Jesse J.
    Xiao, Yonghong
    Jin, Lei
    Kuntz, Kevin W.
    Chesworth, Richard
    Moyer, Mike P.
    Bernt, Kathrin M.
    Tseng, Jen-Chieh
    Kung, Andrew L.
    Armstrong, Scott A.
    Copeland, Robert A.
    Richon, Victoria M.
    Pollock, Roy M.
    [J]. CANCER CELL, 2011, 20 (01) : 53 - 65
  • [14] AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes
    Deshpande, Aniruddha J.
    Deshpande, Anagha
    Sinha, Amit U.
    Chen, Liying
    Chang, Jenny
    Cihan, Ali
    Fazio, Maurizio
    Chen, Chun-wei
    Zhu, Nan
    Koche, Richard
    Dzhekieva, Liuda
    Ibanez, Gloria
    Dias, Stuart
    Banka, Deepti
    Krivtsov, Andrei
    Luo, Minkui
    Roeder, Robert G.
    Bradner, James E.
    Bernt, Kathrin M.
    Armstrong, Scott A.
    [J]. CANCER CELL, 2014, 26 (06) : 896 - 908
  • [15] Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
    Deshpande, Aniruddha J.
    Chen, Liying
    Fazio, Maurizio
    Sinha, Amit U.
    Bernt, Kathrin M.
    Banka, Deepti
    Dias, Stuart
    Chang, Jenny
    Olhava, Edward J.
    Daigle, Scott R.
    Richon, Victoria M.
    Pollock, Roy M.
    Armstrong, Scott A.
    [J]. BLOOD, 2013, 121 (13) : 2533 - 2541
  • [16] Chromatin modifications as therapeutic targets in MLL-rearranged leukemia
    Deshpande, Aniruddha J.
    Bradner, James
    Armstrong, Scott A.
    [J]. TRENDS IN IMMUNOLOGY, 2012, 33 (11) : 563 - 570
  • [17] The many faces of histone H3K79 methylation
    Farooq, Zeenat
    Banday, Shahid
    Pandita, Tej K.
    Altaf, Mohammad
    [J]. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2016, 768 : 46 - 52
  • [18] Early mammalian erythropoiesis requires the Dot1L methyltransferase
    Feng, Yi
    Yang, Yanping
    Ortega, Manoela M.
    Copeland, Jessica N.
    Zhang, Mingcai
    Jacob, Jennifer B.
    Fields, Timothy A.
    Vivian, Jay L.
    Fields, Patrick E.
    [J]. BLOOD, 2010, 116 (22) : 4483 - 4491
  • [19] Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states
    Frederiks, Floor
    Tzouros, Manuel
    Oudgenoeg, Gideon
    van Welsem, Tibor
    Fornerod, Maarten
    Krijgsveld, Jeroen
    van Leeuwen, Fred
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (06) : 550 - 557
  • [20] Functional interdependence of BRD4 and DOT1L in MLL leukemia
    Gilan, Omer
    Lam, Enid Y. N.
    Becher, Isabelle
    Lugo, Dave
    Cannizzaro, Ester
    Joberty, Gerard
    Ward, Aoife
    Wiese, Meike
    Fong, Chun Yew
    Ftouni, Sarah
    Tyler, Dean
    Stanley, Kym
    MacPherson, Laura
    Weng, Chen-Fang
    Chan, Yih-Chih
    Ghisi, Margherita
    Smil, David
    Carpenter, Christopher
    Brown, Peter
    Garton, Neil
    Blewitt, Marnie E.
    Bannister, Andrew J.
    Kouzarides, Tony
    Huntly, Brian J. P.
    Johnstone, Ricky W.
    Drewes, Gerard
    Dawson, Sarah-Jane
    Arrowsmith, Cheryl H.
    Grandi, Paola
    Prinjha, Rab K.
    Dawson, Mark A.
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2016, 23 (07) : 673 - 681